Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Controlled Release

• Publication date

  2010-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jconrel.2010.02.026PMID 20219607
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intraperitoneal Drug Delivery of Antineoplastics

  2012cited by this paper
• Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells.

  2009cited by this paper
• Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.

  2009cited by this paper
• Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.

  2009cited by this paper
• Protein nanoparticles as drug carriers in clinical medicine.

  2008cited by this paper
• Therapeutic Nanoparticles for Drug Delivery in Cancer

  2008cited by this paper
• Nanoparticles for drug delivery in cancer treatment.

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Active targeting schemes for nanoparticle systems in cancer therapeutics.

  2008cited by this paper
• Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging

  2008cited by this paper
• Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.

  2007cited by this paper
• Herceptin: mechanisms of action and resistance.

  2006cited by this paper
• Principles and practice of intraperitoneal chemotherapy for ovarian cancer

  2006cited by this paper
• Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Estimates of the cancer incidence and mortality in Europe in 2006.

  2006cited by this paper
• Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting

  2006cited by this paper
• Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination.

  2006cited by this paper
• Targeted nanoparticles for detecting and treating cancer

  2006cited by this paper
• Models of ovarian cancer--are we there yet?

  2005cited by this paper
• Future options for first‐line therapy of advanced ovarian cancer

  2005cited by this paper
• Drug targeting with nano-sized carrier systems

  2005cited by this paper
• Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis

  2004cited by this paper
• Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress.

  2004cited by this paper
• In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer

  2004cited by this paper
• Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group.

  2004cited by this paper
• Intraperitoneal antineoplastic drug delivery: rationale and results.

  2003cited by this paper
• Primary ovarian cancer chemotherapy: current standards of care

  2003cited by this paper
• Chemotherapeutic management of advanced ovarian cancer.

  2003cited by this paper
• Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

  2003cited by this paper
• Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.

  2003cited by this paper
• Ligand-targeted liposomal anticancer drugs.

  2003cited by this paper
• Nanoparticles in cancer therapy and diagnosis.

  2002cited by this paper
• Advancing animal models of neoplasia through in vivo bioluminescence imaging.

  2002cited by this paper
• Paclitaxel and its formulations.

  2002cited by this paper
• Ligand-targeted therapeutics in anticancer therapy

  2002cited by this paper
• Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity.

  2002cited by this paper
• Determinants of drug delivery and transport to solid tumors.

  2001cited by this paper
• Long-circulating and target-specific nanoparticles: theory to practice.

  2001cited by this paper
• Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

  2000cited by this paper
• Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.

  2000cited by this paper
• Cancer of the ovary.

  1993cited by this paper
• Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.

  1992cited by this paper

• From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors

  2025cites this paper
• Advances in nanocarriers for targeted drug delivery and controlled drug release.

  2025cites this paper
• The optimization strategies of LNP-mRNA formulations: Development and challenges for further application

  2024cites this paper
• The journey of nanoparticles in the abdominal cavity: Exploring their in vivo fate and impact factors.

  2024cites this paper
• Nanomedicine-based targeting delivery systems for peritoneal cavity localized therapy: A promising treatment of ovarian cancer and its peritoneal metastasis

  2024cites this paper
• The role of protein corona on nanodrugs for organ-targeting and its prospects of application.

  2023cites this paper
• Statistical Experimental Approach in Designing pH-Sensitive Oxaliplatin Lipid Nanoparticles for Application in Colorectal Cancer Therapy

  2023cites this paper
• Cell surface GRP78: a potential mechanism of therapeutic resistant tumors

  2023cites this paper
• Review on Nanoparticles and Nanostructured Materials: Bioimaging, Biosensing, Drug Delivery, Tissue Engineering, Antimicrobial, and Agro-Food Applications

  2022cites this paper
• Anti-PADI4 antibody suppresses breast cancer by repressing the citrullinated fibronectin in the tumor microenvironment.

  2022cites this paper
• Tracing New Landscapes in the Arena of Nanoparticle-Based Cancer Immunotherapy

  2022cites this paper
• Multiplexed Analysis of the Cellular Uptake of Polymeric Nanocarriers.

  2022cites this paper
• OVERVIEW OF AN OVARIAN CANCER AND ITS TREATMENT ASPECTS

  2021cites this paper
• Nanotechnology and Its Potential Implications in Ovary Cancer

  2021cites this paper
• A PD1 targeted nano-delivery system based on epigenetic alterations of T cell responses in the treatment of gastric cancer

  2021cites this paper
• A futuristic insight into a “nano-doctor”: A clinical review on medical diagnosis and devices using nanotechnology

  2020cites this paper
• The application of nanotechnology in cancer immunotherapy

  2020cites this paper
• Tuning the Physicochemical Characteristics of Particle-Based Carriers for Intraperitoneal Local Chemotherapy

  2020cites this paper
• Drug delivery systems to prevent peritoneal metastasis after surgery of digestives or ovarian carcinoma: A review.

  2020cites this paper
• Antineoplastic nano-lipobubbles for passively targeted ovarian cancer therapy.

  2019cites this paper
• Development, characterization and biological in vitro assays of paclitaxel-loaded PCL polymeric nanoparticles.

  2019cites this paper
• Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy.

  2019cites this paper
• Nanotechnology: The Future for Cancer Treatment

  2019cites this paper
• RETRACTED ARTICLE: Nanoscale drug delivery strategies for therapy of ovarian cancer: conventional vs targeted

  2019cites this paper
• Exosome-mimetic nanoplatforms for targeted cancer drug delivery

  2019cites this paper
• The use of nanotechnology for treatment of multidrug resistant ovarian cancer cells

  2019cites this paper
• Targeted antifungal liposomes

  2019cites this paper
• Dectin-1-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy

  2019cites this paper
• Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide–Generating Agents Improves the Therapeutic Effects of Nanomedicines

  2018cites this paper
• Nanomedicine: An effective tool in cancer therapy.

  2018cites this paper
• Light sheet microscopy and SrAl2O4 nanoparticles codoped with Eu2+/Dy3+ ions for cancer cell tagging

  2018cites this paper
• Particle Targeting in Complex Biological Media

  2018cites this paper
• A stent film of paclitaxel presenting extreme accumulation of paclitaxel in tumor tissue and excellent antitumor efficacy after implantation beneath the subcutaneous tumor xenograft in mice

  2018cites this paper
• Nanoparticles as Carriers of Proteins, Peptides and Other Therapeutic Molecules

  2018cites this paper
• Nanomedicine‐based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?☆

  2017cites this paper
• Enhanced antiproliferative activity of antibody-functionalized polymeric nanoparticles for targeted delivery of anti-miR-21 to HER2 positive gastric cancer

  2017cites this paper
• Circulating GRP78 antibodies from ovarian cancer patients: a promising tool for cancer cell targeting drug delivery system?

  2017cites this paper
• Oxaliplatin immunohybrid nanoparticles in vitro synergistic suppression evaluation in treatment of colorectal cancer

  2017cites this paper
• Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine

  2017cites this paper
• Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application

  2016cites this paper
• Polymerizable Peptide Monomers for the Targeted and Intracellular Delivery of Cancer Therapeutics

  2016cites this paper
• Mécanismes de relocalisation de la Glucose-regulated protein 78 à la surface des cellules du cancer de l'ovaire

  2016cites this paper
• Exploring the intraperitoneal route of administration for siRNA delivery in the treatment of pertitoneal carcinomatosis

  2016cites this paper
• Applications for Drug Development

  2016cites this paper
• Effect of an Albumin-Coated Mesoporous Silicon Nanoparticle Platform for Paclitaxel Delivery in Human Lung Cancer Cell Line A549

  2016cites this paper
• Formulation and optimization of oxaliplatin immuno-nanoparticles using Box–Behnken design and cytotoxicity assessment for synergistic and receptor-mediated targeting in the treatment of colorectal cancer

  2016cites this paper
• Targeted Nanocurcumin Therapy Using Annexin A2 Anitbody Improves Tumor Accumulation and Therapeutic Efficacy Against Highly Metastatic Breast Cancer.

  2016cites this paper
• Nanooncology in ovarian cancer treatment.

  2016cites this paper
• Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status.

  2016cites this paper
• Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors

  2016cites this paper
• Lipid Nanoparticles and their Application in Nanomedicine.

  2016cites this paper
• Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparticles: a full study to provide the proof of principle from in vitro to in vivo.

  2015cites this paper
• Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.

  2015cites this paper
• A novel antineoplastic nano-lipobubble drug delivery system for passively targeted ovarian cancer therapy

  2015influential citation
• Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.

  2015cites this paper
• Multistage vector (MSV) therapeutics.

  2015cites this paper
• Drug delivery systems for ovarian cancer treatment: a systematic review and meta-analysis of animal studies

  2015cites this paper
• An overview of targeted cancer therapy

  2015cites this paper
• Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab

  2015cites this paper
• Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors.

  2014cites this paper
• Nanocarrier for Poorly Water-Soluble Anticancer Drugs—Barriers of Translation and Solutions

  2014influential citation
• A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma

  2014cites this paper
• The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate.

  2014cites this paper
• Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics.

  2014cites this paper
• Implementation of Nanoparticles in Cancer Therapy

  2014cites this paper
• Overview of the role of nanotechnological innovations in the detection and treatment of solid tumors

  2014cites this paper
• The nano-plasma interface: Implications of the protein corona.

  2014cites this paper
• Preparation of camptothecin-loaded targeting nanoparticles and their antitumor effects on hepatocellular carcinoma cell line H22

  2014cites this paper
• Paclitaxel-loaded PCL-TPGS nanoparticles: in vitro and in vivo performance compared with Abraxane®.

  2014cites this paper
• Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.

  2014cites this paper
• Hyaluronan Polymer Length, Grafting Density, and Surface Poly(ethylene glycol) Coating Influence in Vivo Circulation and Tumor Targeting of Hyaluronan-Grafted Liposomes

  2014cites this paper
• Ligand-Conjugated Nanoparticles of Biodegradable Polymers for Targeted Delivery of Imaging and Therapeutic agents to Biological Cells

  2014cites this paper
• Curcumin-loaded PLGA nanoparticles conjugated with anti- P-glycoprotein antibody to overcome multidrug resistance.

  2014cites this paper
• GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78

  2013cites this paper
• Nanocarriers for the targeted treatment of ovarian cancers.

  2013cites this paper
• Assembly, characterization and evaluation of a 3rd generation nanoparticle based drug carrier for metastatic breast cancer treatment

  2013cites this paper
• Nanomedicinas: lo esencial es invisible...al microscopio óptico

  2013cites this paper
• Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells.

  2013cites this paper
• Non‐invasive molecular imaging for preclinical cancer therapeutic development

  2013cites this paper
• Biocompatibility, absorption and safety of protein nanoparticle-based delivery of doxorubicin through oral administration in rats

  2013cites this paper
• Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel.

  2013cites this paper
• A LOCALIZED CONTROLLED DELIVERY SYSTEM UTILIZING A BLOCK COPOLYMER TO IMPROVE THE CURRENT PARADIGM OF CHEMOTHERAPY

  2013cites this paper
• Assembly of Bio-Nanoparticles for Double Controlled Drug Release

  2013cites this paper
• Single-antibody, targeted nanoparticle delivery of camptothecin.

  2013cites this paper
• Conjugação de anticorpo anti-antígeno carcinoembrionário a nanopartículas magnéticas : avaliação do potencial para detecção e tratamento de câncer

  2012cites this paper
• Polymer nanoparticles--a novel strategy for administration of Paclitaxel in cancer chemotherapy.

  2012cites this paper
• Sustained Intraperitoneal Chemotherapy via an Injectable Depot Delivery System for the Treatment of Ovarian Cancer

  2012cites this paper
• Absorption, pharmacokinetics and disposition of biodegradable nanoscale preparations.

  2012cites this paper
• Analysis on the current status of targeted drug delivery to tumors.

  2012cites this paper
• Nanocarriers for ovarian cancer active drug targeting

  2012cites this paper
• Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination

  2012cites this paper
• Anti-KDEL-coated nanoparticles: a promising tumor targeting approach for ovarian cancer?

  2012cites this paper
• The ligand nanoparticle conjugation approach for targeted cancer therapy.

  2012cites this paper
• Pharmaceutical technology at the service of targeted drug delivery.

  2012cites this paper
• Recent advances in drug delivery strategies for treatment of ovarian cancer

  2012cites this paper
• Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles.

  2012cites this paper
• Recent advances in the application of antibodies as therapeutics.

  2012cites this paper
• Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells.

  2012cites this paper
• Polymeric nanomedicines as a promising vehicle for solid tumor therapy and targeting.

  2012cites this paper
• Nanomedicine in Cancer

  2011cites this paper